Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients

Abstract High‐dose chemotherapy and autologous stem cell transplantation (ASCT) are too toxic for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL). Therefore, effective and tolerable regimens for elderly patients are urgently needed. The present phase II study asses...

Full description

Bibliographic Details
Main Authors: Satoshi Yamasaki, Akiko Kada, Ilseung Choi, Hiroatsu Iida, Naohiro Sekiguchi, Naoko Harada, Morio Sawamura, Takeshi Shimomura, Takuya Komeno, Takahiro Yano, Isao Yoshida, Shinichiro Yoshida, Kazutaka Sunami, Terutoshi Hishita, Hiroshi Takatsuki, Koichi Ohshima, Morishige Takeshita, Akiko M. Saito, Hiromi Iwasaki, Hirokazu Nagai
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:eJHaem
Subjects:
diffuse large B‐cell lymphoma
elderly patients
gemcitabine
quality of life
relapsed
rituximab
Online Access:https://doi.org/10.1002/jha2.111

Internet

https://doi.org/10.1002/jha2.111

Similar Items